Synergistic Effect between Ginsenoside or Urovaxom® with Ciprofloxacin on Chronic Bacterial Prostatitis Rat Model

Abstract

Purpose: Chronic bacterial prostatitis (CBP) is one of the most common urological diseases in adult males, for which antibiotic therapy is the gold standard treatment. However, long-term therapy has many side effects and results in antibiotic resistance. For these reasons, a new treatment modality, which can replace the traditional antibiotic therapy, is required. Ginsenoside has various confirmed bacterial clearance effects in the respiratory system and on immune modulation. UrovaxomR also has confirmed effects on immune modulation, with a preventive effect on recurrent urinary tract infection (UTI). Therefore, the anti-bacterial and synergistic effects of ginsenoside and UrovaxomR were evaluated for the treatment of CBP in ananimal model. Materials and Methods: The 60 rats demonstrating CBP were randomly divided into 6 groups; the control, ciprofloxacin, ginsenoside, UrovaxomR, ciprofloxacin with ginsenoside, and ciprofloxacin with UrovaxomR groups. All drug treatments were conducted for 2 weeks. After treatment, the results were analysed microbiologically and histopathologically. Results: The microbiological cultures of the prostate and urine samples and the histological findings of the prostate demonstrated reduced bacterial growth and improved inflammatory responses in all the experimental groups compared with the control group. The ciprofloxacin, and UrovaxomR with ciprofloxacin groups showed statistically significant decreases in bacterial growth and improvements in inflammatory responses compared to the control group (p 0.05), but the mean difference was very large. Conclusions: Ginsenoside and UrovaxomR may be effective materials in CBP treatment, and has synergistic effects as a combination treatment. Therefore, the combination therapy of ginsenoside with ciprofloxacin or UrovaxomR with ciprofloxacin will be effective treatments of CBP. (Korean J Urol 2007;48:849-857) 󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏